Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Safety Information For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Invega (paliperidone) Extended-Release Tablets, Alza Corp, Approval | Invega (paliperidone) Extended-Release Tablets, Alza Corp., Approval | Invega (paliperidone ER) Tablets, Johnson & Johnson, Efficacy Supp. w/Clinical Data | Invega (paliperidone) Extended-Release Tablets, Janssen LP, Labeling Revision | Invega (paliperidone) Extended-Release Tablets, Johnson & Johnson Pharmaceutical Research & Development, LLC, Labeling Revision | Invega (paliperidone) Extended-Release Tablets, Johnson & Johnson Pharmaceutical Research & Development, LLC, Manufacturing Change or Addition | Invega (paliperidone) Extended-Release Tablets, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Labeling Revision | Invega (paliperidone) Extended-Release Tablets, Johnson & Johnson Pharmaceutical R & D, LLC, Labeling Revision | Invega (paliperidone) Extended Release Tablets, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Labeling Revisions | Invega Sustenna (paliperidone palmitate) Extended-Release Intramusculuar Suspension, Ortho-McNeil-Jansen Pharmaceuticals, Inc., Approval | Invega (paliperidone) Extended-Release Tablets, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Labeling Revision | Invega (paliperidone) Extended-Release Tablets, Johnson & Johnson Pharmaceutical, Labeling Revision | Invega Sustenna (paliperidone palmitate) Extended-Release Intramuscular Suspension, Ortho-McNeil-Jansen Pharmaceuticals, Inc., Labeling Revision | Invega (paliperidone) Extended-Release Tablets, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Labeling Revision | Invega (paliperidone) Extended-Release Tablets, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Labeling Revision | Invega (paliperidone) Extended-Release Tablets, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Efficacy Supplement with Clinical Data to Support | Invega Sustenna (paliperidone palmitate) Extended-Release Injectable Suspension, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Labeling Revision | Invega Sustenna (paliperidone palmitate) Extended-Release Intramuscular Suspension, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Labeling Revision ^ FDA's latest approval appears at the bottom of this list. ^                                                                       A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | For Industry | DMF Index | Pharma Job Search | Pharma Company News | Best Phone © 2012 Betterchem.com